Welcome, Guest. Please login or register.
July 22, 2024, 03:29:02 am

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 204
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 52
Total: 52


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Machine Learning Tool Can Predict Risk of Fatty Liver Disease  (Read 10056 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Machine Learning Tool Can Predict Risk of Fatty Liver Disease
« on: November 25, 2019, 10:17:27 am »
Researchers developed a machine-learning tool that can predict the risk of non-alcoholic steatohepatitis (NASH) among people with other health conditions.

Jörn Schattenberg, MD, of the department of medicine at the University Medical Center in Mainz, Germany, presented findings from the study at the Annual Meeting of the American Association for the Study of Liver Diseases in Boston (The Liver Meeting). The research team also included investigators from Novartis Pharma AG in Basel, Switzerland, and ZS Associates in New Jersey.

NASH and its less severe form, non-alcoholic liver disease (NAFLD), occur when fat accumulates in the liver. Over time, this can lead to fibrosis (scarring), cirrhosis and liver cancer.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.